About the role

Mavericks Wanted

When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on
 
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible. 
 
Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.

Associate Director, Evidence Generation – AI-Enabled Cardiovascular Innovation

Department: Medical Affairs
Reports to: VP, Evidence Generation

What You’ll Do
Support the generation and communication of clinical and real-world evidence for AI-enabled cardiovascular solutions in ATTR-CM.

This role will help advance AI-driven insights across diagnosis and disease management, with a key focus on coordinating BBIO's collaboration with Yale CarDS.

You will work cross-functionally and externally to support adoption and scientific credibility of AI initiatives.

Responsibilities

- Support design and execution of evidence generation activities for AI-enabled tools in cardiovascular disease
- Act as day-to-day liaison with Yale CarDS to coordinate research activities and maintain alignment
- Contribute to development of clinical and real-world evidence on AI applications in diagnosis and patient management
- Support external engagement with academic partners, investigators, and other stakeholders
- Assist in development of publications, presentations, and scientific materials
- Help maintain collaborations with external partners in AI and cardiovascular research

Where You’ll Work
This is a U.S.-based remote role with periodic travel for collaboration with Yale CarDS and attendance at scientific meetings.

Who You Are

- Advanced degree (MD, PhD, PharmD, MPH, MS, or similar) in a relevant field
- ~4–6 years of experience in Medical Affairs, evidence generation, AI, data analytics, or digital health preferred
- Strong organizational and collaboration skills, with ability to manage external partnerships
- Effective scientific communication skills (written and verbal)
- Willingness to travel (~20%)

At BridgeBio, we strive to provide a market-competitive total rewards package, including base pay, an annual performance bonus, company equity, and generous health benefits. Below is the anticipated salary range for candidates for this role who will work in California. The final salary offered to a successful candidate will depend on several factors that may include but are not limited to the type and length of experience within the job, type, and

Skills & Tags

ai ios data analytics design

Aplyr's read

BridgeBio Pharma is a dynamic biotechnology firm dedicated to tackling genetic diseases and cancers, attracting professionals passionate about impactful medical advancements.
Synthesized from recent postings & public sources

What's promising

•BridgeBio focuses on innovative treatments for genetic diseases, offering significant potential for groundbreaking medical advancements.
•The company has a robust pipeline with multiple late-stage clinical trials, indicating strong future growth prospects.
•BridgeBio's strategic partnerships enhance its research capabilities and expand its therapeutic reach.

What to watch

•The company faces high financial risk due to significant R&D expenditures without guaranteed success.
•BridgeBio operates in a highly competitive market with numerous established players.
•Regulatory hurdles for drug approvals can delay product launches and impact revenue.

Why BridgeBio Pharma

•BridgeBio's focus on genetic diseases and cancers sets it apart in the biotechnology sector.
•The company's decentralized model allows for nimble and efficient project management.
•BridgeBio's commitment to rare diseases addresses unmet medical needs, differentiating its mission.

Aplyr’s read is generated by AI from public sources. Was it useful?